Drug Trial Radar · NCT07478744
A Phase 2a Efficacy, Safety, Tolerability, and PK Study of SYT-510 in Participants With Generalized Anxiety Disorder
Last checked: Nov 20, 2026Latest source record: Jun 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
24
Planned (sponsor's estimate)
Start
Apr 22, 2026
Primary completion
Jan 2027
Study completion Jan 2027
Sponsor
- Lead sponsor
- Synendos Therapeutics AGIndustry
- Sponsor type
- Industry
- First posted
- Mar 17, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a single dose study to investigate the efficacy, safety, tolerability and the PK, of SYT-510 in participants who meet diagnostic criteria of GAD. This study represents an evaluation of the effects of SYT-510 in participants meeting DSM-5 GAD diagnostic criteria. As a single dose study, it is designed to evaluate the efficacy of SYT-510 on neurobiological and behavioral markers associated with anxiety and will inform the design of future clinical trials in anxiety disorders. By integrating efficacy / PD, safety, tolerability, and PK measures within the same study framework, the study enables the translational value of the program, ensuring a more comprehensive understanding of SYT-510 effects in patients with generalized anxiety disorders. The plan is to evaluate a single dose of SYT-510 as compared with its matching placebo in a two-way crossover design, separated by a washout period of 7 to 14 days.
Conditions
- Generalized Anxiety Disorder
Interventions
SYT-510Drug
SYT-510 will be administered as a single oral dose in the morning with liquid.
PlaceboDrug
Matching placebo will be administered as a single oral dose in the morning with liquid.
Primary outcomes
What the sponsor says the trial is designed to measure.
- BOLD fMRI signal in the amygdala in response to fearful stimuliTime frame: 7 hours post-dose on Day 2 Treatment period 1 and Day 2 Treatment period 2
- Defensive behavior: Joystick Operated Runway Task (JORT) Flight IntensityTime frame: 4 hours post-dose, Day 2 Treatment period 1 and Day 2 Treatment period 2
- Defensive behavior: Joystick Operated Runway Task Risk Assessment IntensityTime frame: 4 hours post-dose, Day 2 Treatment Period 1 and Day 2 Treatment period 2
- Subjective dread during Joystick Operated Runway Task (JORT)Time frame: 4 hours post-dose, Day 2 Treatment Period 1 and Day 2 Treatment period 2
- Approach-avoidance learning: reward-punishment sensitivity indexTime frame: 4 hours post-dose, Day 2 Treatment period 1 and Day 2 Treatment period 2
- Approach-avoidance learning: punishment sensitivity indexTime frame: 4 hours post-dose, Day 2 Treatment period 1 and Day 2 Treatment period 2
- Default Mode Network connectivity (fMRI)Time frame: 7 hours post dose, Day 2 Treatment period 1 and Day 2 Treatment period 2
- Reaction time to fearful faces (fMRI task)Time frame: 7 hours post-dose, Day 2 Treatment period 1 and Day 2 Treatment period 2
- Self reported State Trait Anxiety Inventory (STAI) subscale scoreTime frame: 1 day post-dose, on Day 3 Treatment period 1 and Day 3 treatment period 2
Locations
1 site in 1 country. Site status is shown where the registry gives one.
SLaM
London, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.